Professor Craig Anderson is Professor of Neurology and Epidemiology in the Faculty of Medicine at the University of New South Wales, and is a clinical academic neurologist at Royal Prince Alfred Hospital, Sydney, Australia. He is Executive Director of The George Institute China.

Craig holds specialist qualifications in clinical neurology and geriatrics, a PhD in medicine and epidemiology from The University of Western Australia, and is a Senior Principal Research Fellow of the National Health and Medical Research Council (NHMRC) of Australia. He is a past President of the Asia Pacific Stroke Organisation and the Stroke Society of Australasia, and is a member of several specialist societies and an editor for the Cochrane Stroke Group. He has published widely on the clinical and epidemiological aspects of stroke, cardiovascular disease and aged care, and has led several large-scale investigator-initiated epidemiological and clinical trials that have had a major influence on clinical practice guidelines for stroke treatment and prevention.

Brendan Mason is currently Non-Executive Director of Melbourne and Beijing located Orcoda Limited
(ASX:ODA) as CEO he recently led a change management, turnaround, project which will result in Orcoda’s first profit since ASX listing in 1999.
Brendan is best known for his change agent work where seeing through a strategy to completion is needed.
Since 2015 Brendan has assisted 29 Australian MedTech and innovation led companies with their strategy and international strategy implementation.

Brendan’s other current roles include:
• Sino-Oz Limited, Brendan’s Beijing & Hong Kong based advisory firm helping export strategy and execution. Currently Sino-Oz has seven clients.
• Chairman of IoTStream a New Zealand based IT services firm to assist with capital raising, strategy development and an ASX listing
• China Council for Promotion of International Trade (CCPIT) (China’s Austrade), ‘Honored’ Advisor

Recently completed roles include:
• CEO of a South Australian Government technology export initiative called SinoSA. The program encompassed helped tech firms with Asian market entry
• Non-Executive Director of Respiri Limited (ASX:RSH) assisting with a special project to restructure the board. Respiri has developed a medical device that warns of asthma attacks in children.
From 2007 to 2014, Brendan was General Manager of medical devices firm, Cochlear Limited in Greater
China/NEA. He oversaw a rapid nine times revenue growth of the business during his tenure. In 2005
Brendan joined Cochlear as the Head of Global Supply Chain with responsibility for overhauling global
operations.
Prior to Cochlear Brendan worked at an AT&T spin-off Lucent Technologies as Executive Director. He was
responsible for the clean-up of the One.Tel project where One.Tel went into receivership owing Lucent
A$1Bn. The clean-up project saved Lucent from insolvency. He was subsequently appointed to manage
the Telstra account. Lucent’s largest account in the southern hemisphere.
Brendan’s early career was with Caterpillar Tractors as a management cadet and later at Boral Limited (ASX:BLD) where he worked in Corporate Development and led an A$230m improvement project. He also managed the 5-year strategic planning program for 45 business units and developed the prospectus for
the spin-off of Origin Energy from the Boral corporate structure (ASX:ORG).
Brendan is a past Chairman of the Board of the Australian Chamber of Commerce, Beijing. A representative organisation that assists Australian companies operating in China. He has qualifications in Business Operations (Macquarie University) and an MBA (Executive) from the Australian Graduate School of Management at the University of NSW, where he lectured in Microeconomics within the EMBA programme. Brendan currently lives in Beijing, China with his family. He is a permanent resident of Hong Kong. Brendan travels to Australia monthly and still calls Australia home.

Tim manages the Austrade West China team, with responsibility for advancing Australia’s trade and investment relationships with China's fastest growing region - a market of 200 million people across Sichuan, Chongqing, Yunnan and Guizhou.

Tim also leads Austrade China’s International Health team, working to open new opportunities for Australian business in China’s vast and dynamic healthcare, life sciences and aged care markets.

Tim has extensive experience in international business engagement, trade and economic policy development and economic analysis. He has a deep understanding of the Chinese market and the opportunities on offer for Australian business. He has worked closely with a range of Chinese companies investing in Australia.

Tim previously served for over ten years with the Department of Foreign Affairs and Trade, including in Beijing, Shanghai and Canberra. He is fluent in Mandarin.